In pharmacovigilance, high-quality data isn’t just about meeting regulatory checkboxes, it’s a vital cornerstone in protecting patient safety.
When pharmacovigilance falls short, the repercussions can be severe, from misleading safety statistics to, in the worst cases, preventable harm or even death. That’s why data quality is front and center, and the Nordic region offers a compelling example of how robust data can make a real difference.
Although Nordic countries represent just a small fraction of the overall European population, their data features prominently in post-authorisation safety studies. This prominence is largely due to the unique strengths of Nordic datasets:
🟢 Reliable Product Availability: Medications are readily available in Nordic countries and are often available in Quantify’s research data before other geographies
🟢 Comprehensive Longitudinal Follow Up: Decades of patient follow-up allow for the creation of robust patient histories and the detection of rare or delayed adverse events.
🟢 Holistic Data: In addition to clinical information, these datasets capture essential data complementary to clinical data, such as socioeconomic factors, that enhance the understanding of patient outcomes and enable sophisticated analyses required by regulators like the European Medicines Agency and FDA.
Find out more about Quantify’s data and experience conducting safety studies from our experts.
